Sign in
CompletedPhase 1/2

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts

Key facts

Who runs it
Antiva Biosciences
Where
Australia, Kenya, Mexico, and New Zealand24 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
141 people enrolled
Started
27 Mar 2024
Ended
20 Apr 2026
Type of study
Interventional, 11 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ABI-2280
Record updated
17 August 2026

Who can take part

Age
25 years to 55 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Female sex, 25 to 55 years of age
  • Positive hrHPV result on at least 2 consecutive tests prior to randomization, one hrHPV+ result at least 12 months prior to screening
  • Cervical cytology, colposcopy and/or biopsy performed within the last 6 months confirming disease status no greater than low-grade squamous intraepithelial lesions or cervical intraepithelial neoplasia grade 1

Who cannot take part

  • History of biopsy or colposcopy indicating high-grade squamous intraepithelial lesions, or history of endocervical curettage positive for glandular dysplasia
  • Any clinically significant immune suppressing condition
  • History or current diagnosis of cervical cancer, suspected or confirmed
  • Plan to have excision or ablation of cervical or vaginal lesions, or to undergo large loop excision of the transformation zone at any time during the study

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a blinded study to assess safety, tolerability, and efficacy of ABI-2280 vaginal inserts in participants diagnosed with persistent cervical hrHPV infection. This study will have up to 11 cohorts with various dose strengths and regimens. Each cohort will start with a sentinel cohort of 8 participants. Sentinel cohorts may be expanded to include an additional up to 32 participants to provide additional proof of concept data to further understanding of benefit/risk of a given dose/dose regimen.

The 11 groups in the trial

  • Experimental: Cohort 1Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 1) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 2Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 2) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 3Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 3) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 4Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 4) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 5Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 5) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 6Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 6) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 7Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 7) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 8Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 8) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 9Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 9) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 10Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 10) or matching placebo

    Treatment: ABI-2280

  • Experimental: Cohort 11Existing treatment, for comparison

    Participants in this arm will receive either ABI 2280 (Dose 11) or matching placebo

    Treatment: ABI-2280

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts
Record updated
17 August 2026